D-0189-2015 Class II Terminated

Recalled by Oregon Compounding Centers, Inc. Dba Creative Compounds — Wilsonville, OR

FDA drug recall D-0189-2015 was initiated by Oregon Compounding Centers, Inc. Dba Creative Compounds on Oct 6, 2014 and is designated Class II. Reason for recall: Lack of Sterility Assurance: All lots of sterile products compounded by the pharmacy that are not expired due to concerns associated with quality control procedures that present a potential risk to… The recall status is terminated (terminated Jun 30, 2015). Affected quantity: 4 mL.

Recall details

Product Type
Drugs
Report Date
Nov 12, 2014
Initiation Date
Oct 6, 2014
Termination Date
Jun 30, 2015
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
4 mL

Product description

ESTRADIOL CYPIONATE (COMPOUNDED/GRAPESEED OIL), 5 mg/mL, injectable, 1 ml glass vial, RX, Creative Compounds, Wilsonville, OR 97070

Reason for recall

Lack of Sterility Assurance: All lots of sterile products compounded by the pharmacy that are not expired due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.

Distribution pattern

Oregon, Washington

Code information

Lot #: 20140828@15, discard date: 10/12/2014

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0189-2015
openFDA file date
Nov 19, 2026
Loaded by RegDataLab
Nov 20, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Need the full FDA record for Oregon Compounding Centers, Inc. Dba Creative Compounds? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: openFDA record for D-0189-2015. Report a data issue: hello@regdatalab.com.